The clinical trial will evaluate the safety, tolerability and pharmacokinetic properties of ICP-723 in patients with solid tumours, and evaluate the anti-tumour efficacy of ICP-723 on NTRK fusion-positive cancers
Acne affects up to 50 million Americans annually. The last FDA approval of an acne drug with a new MOA occurred nearly 40 years ago
The value of the contract is estimated to be between Rs 20-30 crores per year for the next three years
Acetaminophen extended-release tablets 650 mg is bioequivalent of the reference listed drug Tylenol
The segment delivered strong sales growth of 20% YoY
It is estimated that over 11,000 children across Europe, Middle East, and Africa are affected by achondroplasia and could be eligible for treatment with Voxzogo
Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options
The company has to approach the DCGI for approval to commence the trials
The clinical research organisation located in Hyderabad is a USFDA inspected facility
The manufacture of finished doses will commence in 2022 and at full operational capacity, the annual production is expected to exceed 100 million doses annually
Subscribe To Our Newsletter & Stay Updated
